Publications by authors named "Laura Coates"

Claim this Profile
I
Inhibition of structural damage progression with the selective interleukin-23 inhibitor guselkumab in participants with active PsA: results through week 24 of the phase 3b, randomised, double-blind, placebo-controlled APEX study.
Philip J Mease, Christopher T Ritchlin, Laura C Coates, Alexa P Kollmeier, Bei Zhou

Ann Rheum Dis· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Sonelokimab, an IL-17A/IL-17F-inhibiting nanobody for active psoriatic arthritis: a randomized, placebo-controlled phase 2 trial.
Iain B McInnes, Laura C Coates, Philip J Mease, Alexis Ogdie, Arthur Kavanaugh

Nat Med· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
V
Validity and Psychometric Properties of 3 and 4 Visual Analog Scale in Participants With Psoriatic Arthritis Treated With Guselkumab.
William Tillett, Laura C Coates, Marijn Vis, Miriam Zimmermann, Karissa Lozenski

J Rheumatol· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Influence of Biological Sex on Participant Characteristics, Guselkumab Efficacy and Radiographic Progression in Active Psoriatic Arthritis: Post Hoc Analysis of Three Randomized Trials.
Dafna D Gladman, Lihi Eder, Carlo Selmi, Philip J Mease, Alexis Ogdie, Laura C Coates

Rheumatol Ther· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
High prevalence of MASLD in psoriasis and psoriatic arthritis assessed with multiparametric magnetic resonance imaging.
Lija James, Charlie Diamond, Hussein Al-Mossawi, Anneli Andersson, Prashant Pandya, Laura C Coates

Rheumatology (Oxford)· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effect of a treatment strategy utilising golimumab, methotrexate and corticosteroids versus methotrexate and corticosteroids in early, untreated psoriatic arthritis (GOLMePsA): a single-centre, double-blind, parallel-group, randomised controlled trial.
Gabriele De Marco, Elizabeth M A Hensor, Philip S Helliwell, Shabina Sultan, Sayam R Dubash, Laura C Coates

Lancet Rheumatol· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A retrospective observational study of effectiveness of sequential biologic and targeted synthetic DMARDs in psoriatic arthritis in the UK.
Charlotte E Gollins, Annie Russell, Theresa Smith, Arani Vivekanantham, Mel Brooke, Laura C Coates

Rheumatology (Oxford)· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
K
Key factors contributing to gender inequity in global rheumatology awards: a global survey analysis.
Jessica Day, Lekshmi Minikumari Rahulan, Shikha Singla, Praggya Yaadav, Arsh E Bareen Khan, Laura Coates

Rheumatology (Oxford)· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cohort Study on Drug Survival and Tolerability of Adalimumab Biosimilar Transitioning: Pharmaceutical Properties Do Matter.
Amy C D Peeters, Maike H M Wientjes, Wieland D Müskens, David F Ten Cate, Laura C Coates

Clin Pharmacol Ther· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Psoriatic arthritis flare incidence, definition and risk factors: a systematic review.
Batoul Hojeij, Gonul Hazal Koc, Jolanda J Luime, Marijn Vis, Laura C Coates

Rheumatology (Oxford)· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Relationship of radiographic progression status to low disease activity in patients with psoriatic arthritis receiving secukinumab treatment for two years.
Philip J Mease, Laura C Coates, Corine Gaillez, Alexis Shew, Weibin Bao

Rheumatology (Oxford)· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
PASDAS test-retest reliability in early, untreated PsA: data from the GOLMePsA clinical trial.
Gabriele De Marco, Elizabeth M A Hensor, Dennis McGonagle, Ai Lyn Tan, Laura C Coates

Rheumatology (Oxford)· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Summary of Research: Safety and Efficacy of Bimekizumab in Patients with Psoriatic Arthritis: 2-Year Results from Two Phase 3 Studies.
Philip J Mease, Joseph F Merola, Yoshiya Tanaka, Laure Gossec, Iain B McInnes, Laura C Coates

Rheumatol Ther· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Achieving Precision Medicine in Psoriatic Arthritis: Novel Treatment Strategies and Trial Designs.
Shannon Gunawardana, William Tillett, Laura C Coates

Rheum Dis Clin North Am· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effects of Acute Time-Restricted Eating on Inflammation in Individuals With Psoriasis: Protocol for a Case-Control, Prospective Study.
Sinibaldo Romero Arocha, Kim Han, Rebecca D Huffstutler, Geethika P Thota, Natalie A Macheret, Laura C Coates

JMIR Res Protoc· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy of risankizumab across GRAPPA domains in psoriatic arthritis: a pooled analysis of patients from the phase 3 KEEPsAKE 1 and 2 studies.
Laura C Coates, Ricardo Blanco, Frank Behrens, Alexis Ogdie, Filip Van den Bosch

RMD Open· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Oral Peptide Therapeutics as an Emerging Treatment Modality in Immune-Mediated Inflammatory Diseases: A Narrative Review.
Linda Stein Gold, Kilian Eyerich, Joseph F Merola, Joana Torres, Laura C Coates

Adv Ther· July 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Ethnic disparities in COVID-19 mortality and cardiovascular disease in England and Wales between 2020-2022.
Marta Pineda-Moncusí, Freya Allery, Hoda Abbasizanjani, David Powell, Albert Prats-Uribe, Laura C Coates

Nat Commun· July 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Diagnostic delay and less intensive therapy for people with psoriatic arthritis compared with rheumatoid arthritis: a study nested within an English and Welsh audit data set.
Rachel A Charlton, Emer Gates, Laura C Coates, James Galloway, Neil McHugh

Ann Rheum Dis· June 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Correction: Safety and Efficacy of Bimekizumab in Patients with Psoriatic Arthritis: 2-Year Results from Two Phase 3 Studies.
Philip J Mease, Joseph F Merola, Yoshiya Tanaka, Laure Gossec, Iain B McInnes, Laura C Coates

Rheumatol Ther· June 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Identification of distinct disease activity trajectories in patients with psoriatic arthritis receiving tofacitinib: a post hoc analysis of two phase 3 studies.
Dafna Gladman, William Tillett, David Gruben, Laura C Coates, Stefanie Hahne

RMD Open· June 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
European advances in digital rheumatology: explainable insights and personalized digital health tools for psoriatic arthritis.
Leontios J Hadjileontiadis, Vasileios Charisis, Stelios Hadjidimitriou, Sofia B Dias, George Apostolidis, Laura C Coates

EClinicalMedicine· June 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Corrigendum to Bimekizumab treatment in biologic DMARD-naïve patients with active psoriatic arthritis: 52-week efficacy and safety results from the phase III, randomised, placebo-controlled, active reference BE OPTIMAL study Ann Rheum Dis. 2023;82:1404-1414.
Christopher T Ritchlin, Laura C Coates, Iain B McInnes, Philip J Mease, Joseph F Merola

Ann Rheum Dis· June 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis